DDInter1458 DDInter504
Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes.
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine {u} (Compound) binds {v} (Gene) SLC6A2
SLC6A2 {u} (Gene) is bound by {v} (Compound) Desipramine
Phenylpropanolamine {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Desipramine
Phenylpropanolamine {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Desipramine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atomoxetine
Atomoxetine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alimemazine
Alimemazine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Promethazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promazine
Promazine {u} (Compound) resembles {v} (Compound) Desipramine
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Desipramine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Desipramine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Desipramine (Compound)
Phenylpropanolamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Desipramine (Compound)
Phenylpropanolamine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Desipramine (Compound)
Phenylpropanolamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Desipramine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Atomoxetine (Compound) and Atomoxetine (Compound) resembles Desipramine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Protriptyline (Compound) and Protriptyline (Compound) resembles Desipramine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Promazine (Compound) and Promazine (Compound) resembles Desipramine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Promazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Desipramine (Compound)